al study conducted in China, assessing the biological impact of lifestyle and environmental factors on individuals with sensitive skin.5

Supporting Injectable Aesthetics, Galderma hosted a key symposium at the inaugural Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai in October, highlighting insights and data from our previously announced Phase IV, first-of-its-kind trial evaluating Restylane Lyft®or Contour®in combination with Sculptra to address facial volume loss associated with medication-driven weight loss.6Additional activities included presenting the latest updates from Galderma’s aesthetics portfolio, including Relfydess following the recent approval in the United Arab Emirates.

Building on its commitment to education, Galderma hosted the second edition of the Galderma Aesthetic Injector Network (GAIN) LATAM in São Paulo, Brazil – Latin America’s largest private injectables event – welcoming more than
=*=*=*=*=*=
当前为第11/31页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页